FDA Approves Tafasitamab-cxix for Relapsed or Refractory Follicular Lymphoma

On June 18, the FDA approved tafasitamab-cxix with lenalidomide and rituximab for adults with relapsed or refractory follicular lymphoma.

For more information, read the FDA announcement and the Incyte Corporation press release.

Posted on 6/25/2025